Please use this identifier to cite or link to this item:
|Title:||Recent advances in the management of type 2 diabetes mellitus: a review|
Davies, Melanie J.
|Publisher:||BMJ Publishing Group|
|Citation:||Postgraduate Medical Journal, 2008, 84 (996), pp. 524-531.|
|Abstract:||Type 2 diabetes mellitus (T2DM) is a progressive disorder caused by a combination of insulin resistance and β cell dysfunction. It is associated with an increased and premature risk of cardiovascular disease as well as specific microvascular complications such as retinopathy, nephropathy and neuropathy. In the last 5 years new glucose lowering drugs acting on novel pathways have been developed, licensed and launched, such as the glucagon-like peptide (GLP-1) agonists (exenatide) and dipeptidyl peptidase (DPP-IV) inhibitors such as sitagliptin and vildagliptin. This review looks at these new agents in terms of their mode of action, pharmacokinetics and use in clinical practice. This review also includes new agents in the area of weight loss that may have a positive effect for glucose management—for example, rimonabant.|
|Description:||This paper was published as Postgraduate Medical Journal, 2008, 84 (996), pp. 524-531. It is available from http://pmj.bmj.com/content/84/996/524. Doi: 10.1136/pgmj.2008.067918|
Metadata only entry
|Appears in Collections:||Published Articles, Dept. of Cardiovascular Sciences|
Files in This Item:
There are no files associated with this item.
Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.